Xencor, Inc. (XNCR): Price and Financial Metrics


Xencor, Inc. (XNCR): $33.42

0.06 (+0.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XNCR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

XNCR POWR Grades


  • XNCR scores best on the Sentiment dimension, with a Sentiment rank ahead of 73.37% of US stocks.
  • The strongest trend for XNCR is in Sentiment, which has been heading up over the past 47 weeks.
  • XNCR's current lowest rank is in the Quality metric (where it is better than 9.95% of US stocks).

XNCR Stock Summary

  • Of note is the ratio of Xencor Inc's sales and general administrative expense to its total operating expenses; just 6.25% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Xencor Inc is higher than it is for about just 6.87% of US stocks.
  • As for revenue growth, note that XNCR's revenue has grown 152.48% over the past 12 months; that beats the revenue growth of 95.32% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Xencor Inc, a group of peers worth examining would be ATRA, FGEN, RAPT, MORF, and VIR.
  • Visit XNCR's SEC page to see the company's official filings. To visit the company's web site, go to www.xencor.com.

XNCR Valuation Summary

  • XNCR's EV/EBIT ratio is 79.3; this is 170.65% higher than that of the median Healthcare stock.
  • XNCR's EV/EBIT ratio has moved up 83.4 over the prior 94 months.
  • Over the past 94 months, XNCR's EV/EBIT ratio has gone up 83.4.

Below are key valuation metrics over time for XNCR.

Stock Date P/S P/B P/E EV/EBIT
XNCR 2021-08-31 11.1 3.1 84.0 79.3
XNCR 2021-08-30 11.1 3.1 84.1 79.4
XNCR 2021-08-27 10.8 3.0 82.2 77.5
XNCR 2021-08-26 10.4 2.9 79.4 74.6
XNCR 2021-08-25 10.6 2.9 80.8 76.1
XNCR 2021-08-24 10.5 2.9 79.4 74.7

XNCR Growth Metrics

  • The 5 year revenue growth rate now stands at 560.95%.
  • The 2 year net cashflow from operations growth rate now stands at 296.07%.
  • Its 3 year revenue growth rate is now at 355.04%.
XNCR's revenue has moved up $94,024,000 over the prior 52 months.

The table below shows XNCR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 178.632 -26.402 23.52
2021-03-31 124.274 -44.43 -63.746
2020-12-31 122.694 -5.004 -69.333
2020-09-30 84.356 -41.665 -82.554
2020-06-30 70.75 -44.276 -80.228
2020-03-31 77.146 92.562 -61.244

XNCR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XNCR has a Quality Grade of D, ranking ahead of 9.97% of graded US stocks.
  • XNCR's asset turnover comes in at 0.261 -- ranking 169th of 677 Pharmaceutical Products stocks.
  • MDWD, ALBO, and VRTX are the stocks whose asset turnover ratios are most correlated with XNCR.

The table below shows XNCR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.261 1 0.051
2021-03-31 0.185 1 -0.142
2020-12-31 0.184 1 -0.145
2020-09-30 0.128 1 -0.162
2020-06-30 0.106 1 -0.154
2020-03-31 0.114 1 -0.111

XNCR Price Target

For more insight on analysts targets of XNCR, see our XNCR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $53.55 Average Broker Recommendation 1.41 (Moderate Buy)

XNCR Stock Price Chart Interactive Chart >

Price chart for XNCR

XNCR Price/Volume Stats

Current price $33.42 52-week high $58.35
Prev. close $33.36 52-week low $30.12
Day low $32.51 Volume 164,335
Day high $33.56 Avg. volume 219,288
50-day MA $32.51 Dividend yield N/A
200-day MA $40.55 Market Cap 1.95B

Xencor, Inc. (XNCR) Company Bio


Xencor Inc. is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer. The company was founded in 1997 and is based in Monrovia, California.


XNCR Latest News Stream


Event/Time News Detail
Loading, please wait...

XNCR Latest Social Stream


Loading social stream, please wait...

View Full XNCR Social Stream

Latest XNCR News From Around the Web

Below are the latest news stories about Xencor Inc that investors may wish to consider to help them evaluate XNCR as an investment opportunity.

Xencor, inc (XNCR) Q2 2021 Earnings Call Transcript

XNCR earnings call for the period ending June 30, 2021.

Yahoo | August 5, 2021

Xencor Reports Second Quarter 2021 Financial Results

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a review of recent business and portfolio highlights. Xencor is applying its leading protein engineering tools and XmAb technology to overcome historical challenges in creating therapeutic mol

Business Wire | August 4, 2021

Xencor (XNCR) Q2 Earnings and Revenues Surpass Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 242.62% and 296.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 4, 2021

Xencor to Present at Upcoming Investor Conferences

MONROVIA, Calif., August 02, 2021--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in the following upcoming investor events and conferences:

Yahoo | August 2, 2021

Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a cor

Business Wire | July 28, 2021

Read More 'XNCR' Stories Here

XNCR Price Returns

1-mo 2.99%
3-mo -9.53%
6-mo -27.69%
1-year -19.43%
3-year -26.57%
5-year 35.69%
YTD -23.40%
2020 26.87%
2019 -4.89%
2018 64.96%
2017 -16.72%
2016 80.03%

Continue Researching XNCR

Want to see what other sources are saying about Xencor Inc's financials and stock price? Try the links below:

Xencor Inc (XNCR) Stock Price | Nasdaq
Xencor Inc (XNCR) Stock Quote, History and News - Yahoo Finance
Xencor Inc (XNCR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8565 seconds.